Package Leaflet: Information for the User
Trelegy Ellipta 92micrograms/55micrograms/22micrograms inhalation powder, single dose
fluticasone furoate/umeclidinium/vilanterol
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Contents of the pack
Step-by-step instructions for use
What Trelegy Ellipta is
Trelegy Ellipta contains three active substances called fluticasone furoate, umeclidinium bromide, and vilanterol.
Fluticasone furoate belongs to a group of medicines called corticosteroids, often simply called steroids.
Umeclidinium bromide and vilanterol belong to a group of medicines called bronchodilators.
What Trelegy Ellipta is used for
Trelegy Ellipta is used to treat chronic obstructive pulmonary disease(COPD) in adults. COPD is a long-term disease that gets slowly worse and is characterized by difficulty breathing.
In COPD, the muscles around the airways contract, making it difficult to breathe. This medicine relaxes the muscles in the lungs, reducing swelling and irritation in the smaller airways, and makes it easier for air to get in and out of the lungs. When used regularly, it helps control breathing difficulties and reduces the impact of COPD on daily life.
Trelegy Ellipta should be used every day and not just when you have problems breathing or other COPD symptoms. It should not be used to relieve a sudden attack of shortness of breath or wheezing.If you have this type of attack, you should use a fast-acting "rescue" inhaler (such as salbutamol). If you do not have a fast-acting "rescue" inhaler, contact your doctor.
Do not use Trelegy Ellipta
Warnings and precautions
Consult your doctor before starting to use Trelegy Ellipta
Consult your doctorif you think any of the above conditions apply to you.
Urgent breathing difficulties
If you experience chest tightness, coughing, wheezing, or difficulty breathing immediately after using your Trelegy Ellipta inhaler:
stop using this medicineand seek medical help immediately, as you may have a serious condition called paradoxical bronchospasm.
Eye problems during treatment with Trelegy Ellipta
If you experience eye pain or discomfort, blurred vision for a time, halos, colored images, as well as redness of the eyes during treatment with Trelegy Ellipta:
stop using this medicine and seek medical help immediately. These signs may be due to an acute attack of narrow-angle glaucoma.
Lung infection
If you are using this medicine to treat COPD, you may be at a higher risk of developing a lung infection called pneumonia. See section 4 "Possible side effects" for information on the symptoms to look out for while using this medicine.
Consult your doctor as soon as possible if you develop any of these symptoms.
Children and adolescents
This medicine should not be given to children or adolescents under 18 years of age.
Other medicines and Trelegy Ellipta
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. If you are not sure what your medicine contains, consult your doctor or pharmacist.
Some medicines may affect the way this medicine works or make it more likely that you will have side effects. These include:
Consult your doctor or pharmacistif you are taking any of these medicines. Your doctor may monitor you closely if you are taking any of these medicines, as they may increase the side effects of Trelegy Ellipta.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before using this medicine. If you are pregnant, do not use this medicine unless your doctor tells you to.
It is not known if the components of Trelegy Ellipta can pass into breast milk. If you are breastfeeding, consult your doctor before using Trelegy Ellipta. If you are breastfeeding, do not use this medicine unless your doctor tells you to.
Driving and using machines
This medicine is unlikely to affect your ability to drive or use machines.
Trelegy Ellipta contains lactose
If your doctor has told you that you have an intolerance to some sugars, consult them before using this medicine.
Follow the instructions for using this medicine exactly as your doctor has told you. If you are not sure, ask your doctor or pharmacist again.
The recommended doseis one inhalation every day, at the same time each day. You only need one inhalation a day, as the effect of this medicine lasts for 24 hours.
Do not use more doses than your doctor has told you to.
Use Trelegy Ellipta regularly
It is very important that you use Trelegy Ellipta every day, as your doctor has told you. This will help you not to have symptoms throughout the day and night.
Trelegy Ellipta should notbe used to relieve a sudden attack of shortness of breath or wheezing. If you have this type of attack, you should use a fast-acting "rescue" inhaler (such as salbutamol).
How to use the inhaler
To get the full instructions, read the "Step-by-step instructions for use" at the end of this leaflet.
Trelegy Ellipta is for inhalation use only.
Trelegy Ellipta is ready to use once the tray is opened.
If your symptoms do not improve
If your COPD symptoms (shortness of breath, wheezing, coughing) do not improve or worsen, or if you are using your fast-acting "rescue" inhaler more often than usual:
contact your doctor as soon as possible.
If you use more Trelegy Ellipta than you should
If you accidentally use more medicine than you should, contact your doctor or pharmacist immediately, as you may need medical attention. If possible, show them the inhaler, packaging, or this leaflet. You may notice that your heart beats faster than normal, feel shaky, have visual disturbances, have a dry mouth, or have a headache.
If you forget to use Trelegy Ellipta
Do not inhale a double dose to make up for a forgotten dose. Inhale the next dose at the usual time. If you have wheezing or shortness of breath, use your fast-acting "rescue" inhaler (such as salbutamol), and seek medical advice.
If you stop using Trelegy Ellipta
Use this medicine for as long as your doctor recommends. Do not stop using it until your doctor tells you to, even if you feel better, as your symptoms may worsen.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Allergic reactions
Allergic reactions to Trelegy Ellipta are rare (may affect up to 1 in 1,000 people).
If you get any of the following symptoms after taking Trelegy Ellipta, stop using itand tell your doctor immediately:
Urgent breathing difficulties
If your breathing or wheezing gets worse immediately after using this medicine, stop using itand seek medical help immediately.
Pneumonia (lung infection)in patients with COPD (common side effect)
If you get any of the following symptoms while using Trelegy Ellipta, consult your doctor. They could be symptoms of a lung infection:
Other side effects
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Rare(may affect up to 1 in 1,000 people)
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date is the last day of the month shown.
Do not store above 30°C.
Keep the inhaler in the sealed tray to protect it from moisture and only remove it from the tray immediately before first use. Once the tray is opened, the inhaler can be used for 6 weeks. Write the date that you open the tray on the inhaler label in the space provided. The date should be written as soon as the inhaler is removed from the tray.
If stored in a refrigerator, allow the inhaler to reach room temperature for at least one hour before use.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Trelegy Ellipta composition
The active substances are fluticasone furoate, umeclidinium bromide, and vilanterol.
Each inhalation provides a delivered dose (dose that comes out of the mouthpiece) of 92 micrograms of fluticasone furoate, 65 micrograms of umeclidinium bromide equivalent to 55 micrograms of umeclidinium, and 22 micrograms of vilanterol (as trifenatate).
The other ingredients are lactose monohydrate (see section 2 “Trelegy Ellipta contains lactose”) and magnesium stearate.
Appearance of the product and pack contents
Trelegy Ellipta is a powder for inhalation (single-dose).
The Ellipta inhaler is made up of a light grey plastic body, a beige mouthpiece cover, and a dose counter. It is packaged in a foil laminate strip pack with a peelable foil lid. The pack contains a desiccant to reduce moisture in the pack.
The active substance is presented as a white powder in separate blister strips inside the inhaler. Trelegy Ellipta is available in packs of 1 inhaler containing 14 or 30 doses (for a 14 or 30-day treatment) and in clinical packs containing 90 doses (3 inhalers of 30 doses, for a 90-day treatment). Not all pack sizes may be marketed.
Marketing authorisation holder
GlaxoSmithKline Trading Services Limited
12 Riverwalk
Citywest Business Campus
Dublin 24
Ireland
Manufacturer
Glaxo Wellcome Production
Zone Industrielle No.2
23 Rue Lavoisier
27000 Evreux
France
You can request more information about this medicinal product from the local representative of the marketing authorisation holder:
België/Belgique/Belgien GlaxoSmithKline Pharmaceuticals s.a./n.v. Tel: + 32 (0) 10 85 52 00 | Lietuva UAB “BERLIN-CHEMIE MENARINI BALTIC” Tel: + 370 52 691 947 lt@berlin-chemie.com |
Luxembourg/Luxemburg GlaxoSmithKline Pharmaceuticals s.a./n.v. Belgique/Belgien Tél/Tel: + 32 (0) 10 85 52 00 | |
Ceská republika GlaxoSmithKline s.r.o. Tel: + 420 222 001 111 cz.info@gsk.com | Magyarország Berlin-Chemie/A. Menarini Kft. Tel.: + 36 23501301 bc-hu@berlin-chemie.com |
Danmark GlaxoSmithKline Pharma A/S Tlf: + 45 36 35 91 00 dk-info@gsk.com | Malta GlaxoSmithKline Trading Services Limited Tel: + 356 80065004 |
Deutschland GlaxoSmithKline GmbH & Co. KG Tel.: + 49 (0)89 36044 8701 produkt.info@gsk.com | Nederland GlaxoSmithKline BV Tel: + 31 (0)33 2081100 nlinfo@gsk.com |
Eesti OÜ Berlin-Chemie Menarini Eesti Tel: + 372 667 5001 ee@berlin-chemie.com | Norge GlaxoSmithKline AS Tlf: + 47 22 70 20 00 |
Ελλάδα Menarini Hellas A.E. Τηλ: + 30 210 83161 11-13 | Österreich GlaxoSmithKline Pharma GmbH Tel: + 43 (0)1 97075 0 at.info@gsk.com |
España GlaxoSmithKline, S.A. Tel: + 34 900 202 700 es-ci@gsk.com | Polska GSK Services Sp. z o.o. Tel.: + 48 (0)22 576 9000 |
France Laboratoire GlaxoSmithKline Tél: + 33 (0)1 39 17 84 44 diam@gsk.com Hrvatska Berlin-Chemie Menarini Hrvatska d.o.o. Tel: + 385 1 4821 361 office-croatia@berlin-chemie.com | Portugal GlaxoSmithKline – Produtos Farmacêuticos, Lda. Tel: + 351 21 412 95 00 FI.PT@gsk.com România GlaxoSmithKline Trading Services Limited Tel: + 40 800672524 |
Ireland GlaxoSmithKline (Ireland) Limited Tel: + 353 (0)1 4955000 | Slovenija Berlin-Chemie / A. Menarini Distribution Ljubljana d.o.o. Tel: + 386 (0)1 300 2160 slovenia@berlin-chemie.com |
Ísland Vistor hf. Sími: + 354 535 7000 | Slovenská republika Berlin-Chemie / A. Menarini Distribution Slovakia s.r.o. Tel: + 421 2 544 30 730 slovakia@berlin-chemie.com |
Italia GlaxoSmithKline S.p.A. Tel: + 39 (0)45 7741 111 | Suomi/Finland GlaxoSmithKline Oy Puh/Tel: + 358 (0)10 30 30 30 |
Κύπρος GlaxoSmithKline Trading Services Limited Τηλ: + 357 80070017 | Sverige GlaxoSmithKline AB Tel: + 46 (0)8 638 93 00 info.produkt@gsk.com |
Latvija SIA Berlin-Chemie/Menarini Baltic Tel: + 371 67103210 lv@berlin-chemie.com | United Kingdom (Northern Ireland) GlaxoSmithKline Trading Services Limited Tel: + 44 (0)800 221441 customercontactuk@gsk.com |
Date of last revision of this prospectus:
Other sources of information
Detailed information on this medicinal product is available on the European Medicines Agency website: http://www.ema.europa.eu.
Step-by-step instructions for use
What is the inhaler?
The first time you use Trelegy Ellipta, you do not need to make sure the inhaler is working correctly, as it contains pre-measured doses and is ready to use directly.
Your Trelegy Ellipta inhaler pack contains:
The inhaler is packaged in a tray. Do not open the tray until you are ready to inhale a dose of the medicine. When you are ready to use the inhaler, remove the lid to open the tray. The tray contains a desiccant, to reduce moisture. Dispose of the desiccant bag, do notopen, ingest, or inhale it.
When you take the inhaler out of its tray, it will be in the “closed” position. Do not open the inhaler until you are ready to inhale a dose of the medicine. You should write the “Discard by” date on the space provided on the inhaler label and on the pack. The “Discard by” date is 6 weeks from the date of opening the tray. After this date, the inhaler must not be used anymore.The tray can be discarded once it is opened.
If stored in a refrigerator, let the inhaler reach room temperature for at least 1 hour before use.
The step-by-step instructions for using the inhaler provided below can be used for both the 30-dose Ellipta inhaler (30-day treatment) and the 14-dose Ellipta inhaler (14-day treatment).
If the inhaler lid is opened and closed without inhaling the medicine, the dose will be lost.The lost dose will be retained safely inside the inhaler, but it will not be available for inhalation.
It is not possible to accidentally administer an extra dose or a double dose through one inhalation.
For the 14-dose inhaler, the dose counter will also show half in red when there are less than 10 doses left and then will show half in red with the number 0 after the last dose used. The dose counter will appear completely red if the lid is opened again.
When you are ready to inhale a dose, open the inhaler lid.
Do not shake the inhaler.
Now, the medicine is ready to be inhaled.
As confirmation, the dose counter decreases by 1unit.
Do notbreathe out into the inhaler.
Do notblock the ventilation slots with your fingers.
You may not be able to taste or feel the medicine, even when using the inhaler correctly.
Beforeclosing the lid, the inhaler mouthpiece may be cleaned using a dry tissue.
This will make it less likely that you will get side effects such as mouth or throat ulcers.
The average price of TRELEGY ELLIPTA 92/55/22 micrograms inhalation powder (single dose) in October, 2025 is around 75.87 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.